← Back to Search

Behavioural Intervention

P-COC Intervention for Financial Toxicity in Cancer Patients (P-COC Trial)

N/A
Waitlist Available
Led By Maria Pisu, PhD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Receiving systemic therapy or radiation at University of Alabama at Birmingham O'Neal Comprehensive Cancer Center
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test an intervention to help cancer patients better manage their costs of care, which can be a major burden.

Who is the study for?
This trial is for patients with new diagnoses of ovarian, cervical, uterine, breast or colorectal cancer who have health insurance and can access a phone or the internet. They must be receiving treatment at the University of Alabama at Birmingham O'Neal Comprehensive Cancer Center and agree to complete surveys. It's not open to those who can't read English.
What is being tested?
The study tests a Proactive Cost of Care (P-COC) intervention against usual care. P-COC includes discussions on cost management with an educator and using a Cost Tracking tool designed to help patients manage their healthcare expenses more effectively.
What are the potential side effects?
Since this trial focuses on financial interventions rather than medical treatments, there are no direct physical side effects from participating in the study itself.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am getting cancer treatment at the University of Alabama at Birmingham.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Financial Distress
Secondary study objectives
Anxiety
Depression
Self Efficacy
+1 more
Other study objectives
Health Insurance Knowledge
Health Insurance Literacy

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Proactive Cost of Care (P-COC) interventionExperimental Treatment1 Intervention
One time session with trained educator to review: 1. Cost Information Flyer: Anticipated out of pocket costs flyer by cancer type and stage 2. Cost Tracking workbook: Out-of-pocket cost tracker Participants also review a "Insurance, Employment, and Financial Assistance flyer" Participants will be reminded to track their costs once a month through an automated text message or e-mail based on patient preference. Participants also receive an existing patient pamphlet "Patient and Family Guide"
Group II: Usual CareActive Control1 Intervention
Participants receive an existing patient pamphlet "Patient and Family Guide"

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,642 Previous Clinical Trials
2,332,509 Total Patients Enrolled
32 Trials studying Breast Cancer
4,461 Patients Enrolled for Breast Cancer
O'Neal Comprehensive Cancer Center at UABUNKNOWN
Maria Pisu, PhDPrincipal InvestigatorUniversity of Alabama at Birmingham
1 Previous Clinical Trials
2,000 Total Patients Enrolled

Media Library

Proactive Cost of Care (P-COC) intervention (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05939440 — N/A
Breast Cancer Research Study Groups: Proactive Cost of Care (P-COC) intervention, Usual Care
Breast Cancer Clinical Trial 2023: Proactive Cost of Care (P-COC) intervention Highlights & Side Effects. Trial Name: NCT05939440 — N/A
Proactive Cost of Care (P-COC) intervention (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05939440 — N/A
~18 spots leftby Nov 2025